DTPA Radpharm

DTPA 1990/1

Radpharm DTPA consists or sterile. pyrogen free,Jtapnmsed ingredients which need reconstitution with SOdium Pertecnnetate t"Tc) lfltCClion to produce a tectinetlum [IIIITl-rc) pentetate complex suital>te for renal imaging.
The precise structure of the technetium ("-le) pentetate compleK Is not known at tnls time.
Technetium j-.,.c] pentetate Is a diagnostic pharmaceutical administered by intravenous Injection.


DTPA Radpharm Is supplied as a carton of 5 sterile, pyrogen free. vacuum
sealed Multi-dose 8 ml vials.

Each vial contains 5 mg pentetic acid and 1 mg stannous chloride anhydrous as a lyophilised powder.

The product contains no preservatives.


Technetium 99mTc Pentetate may be used as a renal perfusion imaging pharmaceutical. 

Radiopharmaceuticals should be used only by physicians who are qualified by specific training in the safe use and handling of radionuclides.
Contents of the vial/s are intended only for use in the preparation of 99mTc pentetate.

The radioactivity of the dose should be checked with a suitable instrument immediately prior to administration.

Disposal of all radioactive wastes snouI0 be carried out in accordance with the NH & MRC "Code of Practice for me Disposal or Radioactive Wastes
by tile user"' (1985).

Tecnnetium-99m radiopharmaceuticals should only be given to a pregnant woman If in the judgement of the treating physician the expected benefits outweigh the potential hazards

Tecnnellum-99m is excreted in human milk. Interruption to breast feeding Is necessary after the administration of 99mTc pentetate for a period less than 12hr.

(Reference: L.K. Harding, A. Bossuyt, s. Pellet, C. Remers, J.N. TaI001,
"Recommendations for nuclear medicine physicians regarding breastfeeding mothers", Eur.J.NUCI.Med., 1995, 22, BP17).

For each patient, exposure to ionising radiation must be justifiable on the basis or likely benefit. The activity administered must be such that the resulting dose is as low as reasonably achievable bearing in mind the need to obtain the intended diagnostic or therapeutic result.

Exposure to ionising radlation Is linked with cancer induction and a potential for development of hereditary defects. For diagnostic nuclear medicine investigations the current evidence suggests that these adverse effects will occur with low frequency because or the low radiation doses incurred.

For most diagnostic inves119ations using a nuclear medicine procedure the radiation dose delivered (EDE) Is less than 20 msv. Higher doses may be justified in some clinical circumstances.

In Isolated cases the following adverse reactions have been reported: flushing, dizziness. dyspnoea. itch, urticaria and hypotension.

ARTG entry for Medicine Registered

ARTG No: 14327

Sponsor: Global Medical Solutions Australia Pty Limited T/A Radpharm Scientific

Postal Address: PO Box 3334 BMDC, BELCONNEN, ACT, 2617 Australia

ARTG Start Date: 5/09/1991

Product Category: Medicine

Status: Active

Approval Area: Drug Safety Evaluation Branch

ARTG Summary:

Related Items